ASCO: ovarian suppression + tamoxifen ups breast CA survival

June 5, 2018

(HealthDay)—The addition of ovarian suppression to tamoxifen is associated with increased survival versus tamoxifen alone among premenopausal women with breast cancer, according to a study published online June 4 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.

Prudence A. Francis, M.D., from the University of Melbourne in Australia, and colleagues randomized to five years of tamoxifen, tamoxifen plus ovarian suppression, or plus ovarian suppression in the Suppression of Ovarian Function Trial (SOFT) and to tamoxifen plus ovarian suppression or exemestane plus ovarian suppression in the Tamoxifen and Exemestane Trial (TEXT).

The researchers found that the eight-year disease-free survival rate was 78.9, 83.2, and 85.9 percent for tamoxifen alone, tamoxifen plus ovarian suppression, and exemestane plus ovarian suppression, respectively, in SOFT. The corresponding eight-year overall survival rates were 91.5, 93.3, and 92.1 percent. The eight-year distant recurrence rate was lower with exemestane plus ovarian suppression versus tamoxifen plus ovarian suppression in women with human epidermal growth factor receptor 2-negative cancers who underwent chemotherapy (by 7 and 5 percentage points in SOFT and TEXT, respectively).

"The addition of ovarian suppression to tamoxifen resulted in significantly higher eight-year rates of both disease-free and overall survival than alone," the authors write. "The use of exemestane plus ovarian suppression resulted in even higher rates of freedom from recurrence."

Several authors disclosed ties to pharmaceutical companies, including Pfizer and Ipsen. The study was partially funded by Pfizer; Pfizer and Ipsen provided the trial drugs.

Explore further: AI plus ovarian suppression yields benefit in high-risk younger breast cancer patients

More information: Abstract/Full Text
More Information

Related Stories

AI plus ovarian suppression yields benefit in high-risk younger breast cancer patients

June 4, 2018
Premenopausal women with hormone receptor-positive, HER2-negative breast cancer and a high risk of recurrence who are treated with an aromatase inhibitor plus ovarian function suppression may gain 10 to 15 percent improvement ...

Adding ovarian suppression to tamoxifen reduced recurrence for some women with premenopausal breast cancer

December 12, 2014
Among premenopausal women with early-stage, hormone receptor-positive breast cancer, adding ovarian suppression to tamoxifen reduced breast cancer recurrence for those who had previously received chemotherapy and remained ...

New drug to prevent breast cancer recurrence shows promise

June 1, 2014
A new treatment option is more effective than tamoxifen at preventing a return of breast cancer in young women, according to the results of two international trials released Sunday.

Ovarian cancer is hard to detect

May 12, 2018
Ovarian cancer is estimated to affect more than 22,000 women each year and is the fifth leading cause of cancer deaths among women, according to American Cancer Society.

Six in seven women at high risk of breast cancer shun tamoxifen as a preventative measure

April 24, 2018
Six in seven women with a family history of breast cancer opt out of taking tamoxifen as a preventative measure, according to a study funded by Cancer Research UK and published in Breast Cancer Research and Treatment today.

New ovarian cancer drug licensed for use

December 21, 2017
A new drug to delay the spread of ovarian cancer, which was developed from UCL research, has been licensed for use in the UK.

Recommended for you

'Kiss of death' cancer: How computational geeks may have uncovered a therapy for a deadly disease

June 19, 2018
It's called the 'kiss of death'. Triple negative breast cancer has no targeted drug therapy and, as such, the only hope for these patients is chemotherapy. Triple negative breast cancer is aggressive and deadly. Patients ...

Ovarian cancer cells switched off by 'unusual' mechanism

June 19, 2018
Scientists at the Ovarian Cancer Action Research Centre at Imperial College London have discovered a mechanism that deactivates ovarian cancer cells.

Team discovers gene mutations linked to pancreatic cancer

June 19, 2018
Six genes contain mutations that may be passed down in families, substantially increasing a person's risk for pancreatic cancer. That's according to Mayo Clinic research published in the June 19 edition of the JAMA. However, ...

Breast cancer could be prevented by targeting epigenetic proteins, study suggests

June 19, 2018
Researchers at the Princess Margaret Cancer Centre in Toronto have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone. The study, which will ...

Targeting the engine room of the cancer cell

June 18, 2018
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug ...

Study suggests well-known growth suppressor actually fuels lethal brain cancers

June 18, 2018
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.